Skip to content

Released May 7, 2026, before the open

10-Q filed May 7, 2026, 37 days after period end · 0001628280-26-031726

Q1 2026 · 10-Q
Revenue—
Net Income-$49.12MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.28N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$50,654,000N/M
Operating Cash Flow-$42,710,000N/M
Free Cash Flowderived-$42,924,000N/M

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue—$1.45M$591.00K$0.00
Net Income-$49.12M-$51.89M-$45.76M-$39.40M
EPS Diluted-$0.28-$0.40-$0.44-$0.44

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR